User:Ongmianli/Portfolios/Simple phobia

From Wikipedia, the free encyclopedia

Demographic Information[edit]

This section describes the demographic setting of the population(s) sampled, base rates of diagnosis, country/region sampled and the diagnostic method that was used. Using this information, clinicians will be able to anchor the rate of simple phobia that they are likely to see in their clinical practice.

Setting Reference Base Rate Demography Diagnostic Method
Mexican-American Prevalence and Service Survey (MAPSS) – adults 18+, all specific phobias Vega et al., 1998[1] 7.4% California CIDI/DSM-III-R
NCS replication, adults 18+, 12-month prevalence Kessler et al., 2005[2] 8.7% All of US CIDI/DSM-IV
National Comorbidity Survey (NCS); non-institutionalized adults between 18-54, all specific phobias Kessler et al., 2005[3] 11.3% All of US CIDI/DSM-III-R
National Epidemiologic Survey on Alcohol and Related Conditions (NESARC), adults 18+, all specific phobias Stinson et al., 2007[4] 9.4% All of US AUDADIS-IV/DSM-IV
Adults 18+, all specific phobias Robins et al., 1984[5] 7.8% New Haven, CT Clinical interview/DSM-III
Adults 18+, all specific phobias Robins et al., 1984[5] 23.3% Baltimore, MD Clinical interview/DSM-III
Adults 18+, all specific phobias Robins et al., 1984[5] 11.1% St. Louis, MI Clinical interview/DSM-III
National Epidemiologic Survey on Alcohol and Related Conditions (NESARC), adults 18+, all Specific Phobias Grant et al., 2004[6] 7.14% All of US AUDADIS-IV/DSM-IV

Diagnosis[edit]

Recommended Diagnostic Interviews[edit]

  • Mini-International Neuropsychiatric Interview (MINI)
  • Anxiety Disorders Interview Schedule (ADIS-IV)
  • Structured Clinical Interview for DSM-IV Disorders (SCID)
  • Composite International Diagnostic Interview (CIDI)

Recommended Screening Instruments[edit]

  • Animal type: Spider Phobia Beliefs Questionnaire: see Appendix B
  • Natural environment type: Acrophobia Questionnaire: see Appendix B
  • Blood-injection injury type: Blood Injection Symptom Scale (BISS), Dental Anxiety Inventory
  • Situational type: Claustrophobia Scale (CS)
  • Other type: Specific Phobia of Vomiting Inventory (SPOVI): see Appendix B

(Appendix B found in actual PDF of portfolio)

Diagnostic Criteria[edit]

Diagnostic efficiency information for all included measures is based on criteria from DSM-IV or earlier. As of the compilation of this portfolio, there are no screening tools for all types of specific phobias with strong psychometric properties. The Fear Survey Schedule (FSS) has been popularly used but cannot accurately discriminate between phobics and fearful controls. Screening measures that are not included in the AUC curve table do not have current likelihood ratios available.

The DSM-V criteria for specific phobia has not changed from the DSM-IV. The criteria is as follows:

A. Marked and persistent fear that is excessive or unreasonable, cued by the presence or anticipation of a specific object or situation (e.g. flying, heights, animals, receiving an injection, seeing blood)

B. Exposure to the phobic stimulus almost invariably provokes an immediate anxiety response, which may take the form of a situationally bound or situationally predisposed panic attack. Note: in children, the anxiety may be expressed by crying, tantrums, freezing or clinging.

C. The person recognizes that the fear is excessive and unreasonable. Note: in children this feature may be absent.

D. The phobic situation is avoided or is endured with intense anxiety or distress.

E. The avoidance, anxious anticipation, or distress in the feared situation(s) interferes significantly with a person’s routine, occupational (or academic) functioning, or social activities or relationships or there is a marked distress about having the phobia.

F. In individuals under the age of 18 years the duration is at least 6 months.

G. The anxiety panic attacks or phobic avoidance associated with the specific object or situation are not better accounted for by another mental disorder such as OCD (e.g. fear of dirt in someone with an obsession about contamination), post-traumatic stress disorder (e.g. avoidance of school), social phobia, panic disorder with agoraphobia or agoraphobia without history of panic disorder).

Areas Under the Curve (AUCs) and Likelihood Ratios for Potential Screening Measures for Specific Phobia[edit]

Screening Measure (Primary Reference) AUC and Sample Size LR+ (Score) LR- (Score) Citation Clinical generalizability
Specific Phobia of Vomiting Inventory (SPOVI) 0.944 (N = 185) 24.3 (10+) 0.03 (<10) (Veale et al., 2012)[7] High: able to distinguish between phobics and controls
The Claustrophobia Scale (CS) - Anxiety Subscale (Rachman and Taylor, 1993) --- (N = 285) 49.0 (24+) 0.0002 (<24) (Ost, 2007)[8] High: able to distinguish between phobics and controls
The Claustrophobia Scale (CS) - Avoidance Subscale (Rachman and Taylor, 1993) --- (N = 285) 19.2 (9+) 0.0004 (<9) (Ost, 2007)[8] High: able to distinguish between phobics and controls
  • Note: “LR+” refers to the change in likelihood ratio associated with a positive test score, and “LR-” is the likelihood ratio for a low score. Likelihood ratios of 1 indicate that the test result did not change impressions at all. LRs larger than 10 or smaller than .10 are frequently clinically decisive; 5 or .20 are helpful, and between 2.0 and .5 are small enough that they rarely result in clinically meaningful changes of formulation (Sackett et al., 2000).

Search terms: [specific phobia] AND [sensitivity OR specificity] in Google Scholar and PsycINFO

Treatment[edit]

Two treatments of specific phobia treatment include in-vivo exposure and virtual reality therapy. The former is most effective in specific phobias by hierarchically exposing the client to the fear-inducing stimulus and measuring anxiety response. The latter therapy is most effective in driving and height fears by using computer-generated, interactive virtual environments that the clinician manipulates.

Process and Outcome Measures[edit]

Clinically Significant Change Benchmarks with Common Instruments[edit]

Measure A Cut Score B Cut Score C Cut Score 95% Critical Change (unstandardized scores) 90% Critical Change (unstandardized) SE-difference critical change (unstandardized)
Dental Cognitions Questionnaire (1995 Norms)[9] 9.1 16.4 41.2 4.2 3.6 2.2
The Claustrophobia Questionnaire (2001 Norms) - Total[10] 18.6 67.7 41.2 11. 9.4 5.7
The Claustrophobia Questionnaire (2001 Norms) - Suffocation[10] 7.0 24.9 16.2 5.0 4.3 2.6
The Claustrophobia Questionnaire (2001 Norms) - Restriction[10] 8.4 45.5 24.3 6.9 5.8 3.5
Spider Phobia Questionnaire (1996 Norms)[11] 15.1 20.7 17.3 3.0 2.5 1.5
  • Note: “A” = Away from the clinical range, “B” = Back into the nonclinical range, “C” = Closer to the nonclinical than clinical mean.

Search terms: [specific phobia] AND [adults] AND [clinical significance OR outcomes] in Google Scholar and PsycINFO

Process Measures[edit]

Two types of behavioral approach tests (BAT) can be used to observe patients in typically avoided situations. A progressive BAT gradually exposes the patient to a fear-inducing situation in a step-by-step manner, and responses to each step are recorded. A selective BAT allows the clinician to select one or more challenges from the patient’s hierarchy, and the patient is to complete each challenge to induce a phobic response and rate the inducing fear.

References[edit]

  1. ^ Vega, WA; Kolody, B; Aguilar-Gaxiola, S; Alderete, E; Catalano, R; Caraveo-Anduaga, J (September 1998). "Lifetime prevalence of DSM-III-R psychiatric disorders among urban and rural Mexican Americans in California". Archives of general psychiatry. 55 (9): 771–8. PMID 9736002.
  2. ^ Kessler, RC; Berglund, P; Demler, O; Jin, R; Merikangas, KR; Walters, EE (June 2005). "Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication". Archives of general psychiatry. 62 (6): 593–602. PMID 15939837.
  3. ^ Kessler, RC; Chiu, WT; Demler, O; Merikangas, KR; Walters, EE (June 2005). "Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication". Archives of general psychiatry. 62 (6): 617–27. PMID 15939839.
  4. ^ Stinson, FS; Dawson, DA; Patricia Chou, S; Smith, S; Goldstein, RB; June Ruan, W; Grant, BF (July 2007). "The epidemiology of DSM-IV specific phobia in the USA: results from the National Epidemiologic Survey on Alcohol and Related Conditions". Psychological medicine. 37 (7): 1047–59. PMID 17335637.
  5. ^ a b c Robins, LN; Helzer, JE; Weissman, MM; Orvaschel, H; Gruenberg, E; Burke JD, Jr; Regier, DA (October 1984). "Lifetime prevalence of specific psychiatric disorders in three sites". Archives of general psychiatry. 41 (10): 949–58. PMID 6332590.
  6. ^ Grant, BF; Stinson, FS; Dawson, DA; Chou, SP; Dufour, MC; Compton, W; Pickering, RP; Kaplan, K (August 2004). "Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions". Archives of general psychiatry. 61 (8): 807–16. PMID 15289279.
  7. ^ Veale, David; Ellison, Nell; Boschen, Mark J.; Costa, Ana; Whelan, Chantelle; Muccio, Francesca; Henry, Kareina (18 December 2012). "Development of an Inventory to Measure Specific Phobia of Vomiting (Emetophobia)". Cognitive Therapy and Research. 37 (3): 595–604. doi:10.1007/s10608-012-9495-y.
  8. ^ a b Ost, LG (May 2007). "The claustrophobia scale: a psychometric evaluation". Behaviour research and therapy. 45 (5): 1053–64. PMID 17303070.
  9. ^ de Jongh, A; Muris, P; Schoenmakers, N; ter Horst, G (June 1995). "Negative cognitions of dental phobics: reliability and validity of the dental cognitions questionnaire". Behaviour research and therapy. 33 (5): 507–15. PMID 7598671.
  10. ^ a b c Radomsky, AS; Rachman, S; Thordarson, DS; McIsaac, HK; Teachman, BA (2001). "The Claustrophobia Questionnaire". Journal of anxiety disorders. 15 (4): 287–97. PMID 11474815.
  11. ^ Mulkens, SA; de Jong, PJ; Merckelbach, H (August 1996). "Disgust and spider phobia". Journal of abnormal psychology. 105 (3): 464–8. PMID 8772018.